Compugen (CGEN) Aandeel Koers

Compugen Ltd is primarily active in the biotechnology industry.

Compugen Ltd faces competition from various players in the market. Some of the main competitors of Compugen Ltd include industry giants like Gilead Sciences, Inc., Johnson & Johnson, and Bristol-Myers Squibb Company. These companies, along with others in the pharmaceutical and biotechnology sectors, pose a significant challenge to Compugen Ltd's market presence. However, Compugen Ltd's unique portfolio and innovative approach towards drug discovery and development help differentiate it from competitors and provide a competitive edge.

Compugen Ltd is a renowned biotechnology company based in Israel. Founded in 1993, the company specializes in predictive drug discovery and development using its proprietary computational technologies. With a focus on immuno-oncology, Compugen aims to harness the immune system's power to fight cancer effectively. Over the years, Compugen has established collaborations with leading pharmaceutical and biotech companies to accelerate its drug development programs. They have also generated a robust pipeline of novel, immune checkpoint targets for potential therapeutic interventions. With its innovative approach and strong expertise, Compugen Ltd strives to revolutionize cancer treatment and improve patient outcomes.

Compugen Ltd has achieved numerous significant milestones throughout its history. Some notable accomplishments include the discovery and validation of over 2,300 potential therapeutic targets, the development of innovative platforms for drug discovery, and the establishment of strategic partnerships with leading pharmaceutical companies. Additionally, Compugen Ltd has made advancements in the field of immuno-oncology, with the successful preclinical demonstrations of several novel immune checkpoint targets. These achievements showcase the company's commitment to pioneering research, collaboration, and progress in biotechnology. Compugen Ltd continues to strive towards revolutionizing the development of novel therapeutics for various diseases and solidifying its position as a key player in the industry.

Compugen Ltd is primarily present in the United States, Israel, and Canada.

Compugen Ltd represents values of innovation, collaboration, and scientific excellence. As a leading biotechnology company, they strive to discover and develop novel therapeutic solutions to address unmet medical needs. Their corporate philosophy is centered around harnessing the power of artificial intelligence and deep learning algorithms to enable predictive identification and validation of drug targets. By leveraging their proprietary computational platforms, Compugen Ltd aims to revolutionize the field of immunology and oncology, ultimately improving patient outcomes. Through their commitment to pioneering research and strong partnerships, Compugen Ltd is dedicated to delivering innovative and effective treatments for complex diseases.

Analisten hanteren momenteel een gemiddeld koersdoel van 5,00 USD voor het aandeel Compugen (mediaan: 5,00 USD), oftewel +110,1 % ten opzichte van de laatste koers. De consensus is gebaseerd op 11 analistenratings.

Compugen Koersdoelstellingen analisten 2026

11 analisten beoordelen het aandeel Compugen momenteel: 10 adviseren kopen, 1 houden en 0 verkopen. Voor 2026 verwachten analisten dat Compugen een omzet van 10,20 Miljoen USD en winst per aandeel van -0,28 USD behaalt.

Compugen Koersdoelstellingen analisten 2026

Omgezet tegen de huidige wisselkoers noteert het aandeel Compugen op 2,11 EUR (2,38 USD).

Het aandeel Compugen (CGEN) is genoteerd aan 5 beurzen, waaronder: NASDAQ (CGEN), Frankfurt (CW9.F), Stuttgart (CW9.SG), Berlin (CW9.BE).

Compugen Ltd. is a leading company in the development and marketing of computer-based solutions for biology and medicine. The company utilizes its extensive expertise in the field of bioinformatics to develop innovative software and data analysis tools that are applied in pharmacy, oncology therapies, and diagnostics. The business model of Compugen comprises several divisions. The first one involves the identification of target molecules that can be used for medical purposes. The company utilizes its ability to investigate complex biological data and extract relevant information from the analysis. The resulting insights are used to determine new targets for drug development. Another division of Compugen is drug development. The company focuses on the discovery of novel therapeutic targets and their implementation into successful and efficient medications. Compugen employs state-of-the-art technologies and methods such as immunomodulation and inhibition of tumor growth. Furthermore, the company also has its own diagnostic platform. This platform aims to assist doctors and patients in making more targeted diagnoses and selecting appropriate therapies. Compugen relies on its expertise in the analysis of biomarkers and diagnostic biomolecules. Another area of activity for the company is the development of software products. Compugen offers its customers software tools tailored to specific needs, which support the analysis of biological data and the development of new medications. Overall, the business model of Compugen is characterized by a high focus on innovation and research. The company aims to support its customers in the development of new diagnosis and treatment possibilities based on modern and data-driven bioinformatics. With its products and services, Compugen targets a wide range of applications. From pharmacy to precision medicine and diagnostics, the company offers diverse solutions to its customers. It can draw on a successful history of development partnerships and strategic alliances, which have provided it with important positions and a global presence. In summary, the business model of Compugen Ltd. is shaped by its expertise in bioinformatics, a high willingness to innovate, and close collaboration with customers and partners. Through its various divisions, it offers a broad range of products targeting different application areas and emphasizing high quality and scientific competence.

De verwachte omzet van Compugen bedraagt 10,20 Miljoen USD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.

De verwachte winst van Compugen bedraagt -26,27 Miljoen USD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.

De koers-winstverhouding (P/E) van Compugen bedraagt momenteel -8,58. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Compugen-aandeel in te schatten.

De koers-omzetverhouding (P/S) van Compugen bedraagt momenteel 22,11. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Compugen-aandeel.

De Eulerpool Kwaliteitsscore voor Compugen is 7/10.

De ISIN van Compugen is IL0010852080. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.

De WKN van Compugen is 553001. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.

Het tickersymbool van Compugen is CGEN. Onder dit beurstickersymbool wordt het Compugen-aandeel op de beurs verhandeld.